Xeris Pharma's Hypoglycemia Med Receives European Nod, Shares Spike

by Vandana Singh, Benzinga Editor

February 12, 2021 6:06 AM | 1 min read | Make a Comment

The European Commission has approved Xeris Pharmaceuticals Inc's (NASDAQ: XERS) Ogluo (glucagon) injection to treat severe hypoglycemia in adults, adolescents, and children aged two years and over with diabetes mellitus. Hypoglycemia (low blood sugar level) is a complication of glucose-lowering therapy.
Xeris will complete a further administrative step to obtain a license in Great Britain. No re-examination of clinical data by the U.K. regulatory authority is expected.
In the U.S., the injection is available under the Gvoke PFS and Gvoke HypoPen brand names, approved in September 2019.
Price Action: XERS jumps 17.6% at $7.8 in premarket trading on the last check Friday.

Posted In: Biotech News Health Care Small Cap FDA General European Commission hypoglycemia

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.